# A Phase 1, First-in-human Study of VX-634

> **NCT05579431** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 127 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** VX-634
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05579431
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-13
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-11-13
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579431, "A Phase 1, First-in-human Study of VX-634". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05579431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*